This work follows previous research from our group and others concerning the P465L mouse, a humanized model for the dominant negative mutant P467L‐PPARγ that resembles the phenotype observed in patients and is characterized by a partial lipodystrophy, insulin resistance, hypertension and fatty liver. This evidence concerns the gene PPARG and hypertensive disorder.